This is a UK news story, published by Yahoo, that relates primarily to The European Medicines Agency news.
For more UK news, you can click here:
more UK newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
loss drug Wegovy. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Novo Nordisk news, Wegovy news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
diabetes drug OzempicReuters
•80% Informative
The European Medicines Agency has backed the use of Novo Nordisk's Wegovy to lower major heart risks and strokes in overweight or obese adults without diabetes.
The backing from the European Union drug watchdog's committee comes two days after the UK regulator gave the drug a similar nod.
The U.S. Food and Drug Administration approved the drug for prevention of cardiovascular events in people with obesity.
VR Score
91
Informative language
97
Neutral language
71
Article tone
formal
Language
English
Language complexity
57
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links